


HARMONi-G13 Phase 3 Clinical Study

First-line Metastatic Colorectal Cancer (CRC) / NCT07228832¹




Ivonescimab: PD-1/VEGF Bispecific Antibody Being Studied in Phase 3 CRC Study.
Brings two validated mechanisms in oncology²⁻⁴ into ONE novel tetravalent molecule.



Ivonescimab Blocks Both PD-1 & VEGF Cooperatively

Globally 3,000+ patients have been treated with ivonescimab across Summit and Akeso clinical studies.⁵ Summit is actively recruiting approximately 600 patients worldwide for the HARMONi-G13 clinical study.

HARMONi-G13 STUDY DESIGN



KEY ELIGIBILITY CRITERIA

Key Inclusion Criteria:

- ECOG performance status score of 0 or 1
- Expected life expectancy ≥ 6 months
- Patients with histologically or cytologically confirmed metastatic CRC
- No prior systemic therapy for metastatic CRC
- At least 1 measurable noncerebral lesion

Key Exclusion Criteria:

- Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) disease
- Known BRAF V600E mutant status
- Current presence of significant radiographic or clinical manifestations of gastrointestinal (GI) obstruction
- Ascites requiring paracentesis within last 30 days
- Patients who have received prior immunotherapy or anti-angiogenic therapy for colorectal cancer
- Active or prior history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, or chronic diarrhea)
- Resectable disease

Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China's National Medical Products Administration (NMPA).

Abbreviations: 5-FU=5-fluorouracil; DCR=disease control rate; DOR=duration of response; ECOG PS=Eastern Cooperative Oncology Group performance status; Fc=Fragment crystallizable; HRQoL=health-related quality of life; IRRC=independent radiology review committee; LV=leucovorin; mFOLFOX6=modified FOLFOX6 [Oxaliplatin + Leucovorin + 5-fluorouracil (5-FU)]; ORR=objective response rate; OS=overall survival; PD-1=programmed cell death protein 1; PD-L1=programmed cell death-ligand 1; PFS=progression-free survival; PK=pharmacokinetics; Q2W=every 2 weeks; R=randomization; TME=tumor microenvironment; VEGF=vascular endothelial growth factor.

By use of this QR code you agree to Summit's privacy notice located at smttx.com



Cooperative Binding Offers Potential to Drive Synergistic Activity⁶⁻⁸

Brings two validated mechanisms in oncology²⁻⁴ into ONE novel tetravalent molecule


Dual Blocking of PD-1 & VEGF⁸

Increased Avidity in TME


VEGF-A efficiently enhances the binding affinity to PD-1 by several fold⁸ (*in vitro*)

Enhanced Activity of T Cells


VEGF dimer leads to potential interconnection of ivonescimab molecules, which may increase activity of T cells⁸ (*in vitro*)



Tumor Microenvironment



Tumor Microenvironment with Ivonescimab Cooperative Binding



Images for illustrative purposes only

Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China's National Medical Products Administration (NMPA).

For more information contact medinfo@smmttx.com

HARMONI-GI3



Intended for Clinical Site Staff Use Only

1. Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer (HARMONI-GI3). ClinicalTrials.gov identifier: NCT07228832. <https://clinicaltrials.gov/study/NCT07228832>, Updated Nov 13, 2025 (Accessed Nov 17, 2025); 2. Manegold C, et al. *J Thorac Oncol.* 2017;12(2):194-207; 3. Pardoll D. *Nat Rev Cancer.* 2012;12(4):252-64; 4. Tamura R, et al. *Med Oncol.* 2020;37(1):2; 5. Summit Press Release (October 20, 2025); 6. Zhao Y, et al. *eClinicalMedicine.* 2023;3(62):102106; 7. Wang L, et al. *J Thorac Oncol.* 2024;19(3):465-475; 8. Zhong T, et al. *iScience.* 2025;28:111722.